Corvus Pharmaceuticals Announces FDA Fast Track Designation For Soquelitinib In Treatment Of Relapsed Or Refractory PTCL; Phase 3 Clinical Trial To Begin Initial Enrollment In Q3 2024
Corvus Pharmaceuticals Announces FDA Fast Track Designation For Soquelitinib In Treatment Of Relapsed Or Refractory PTCL; Phase 3 Clinical Trial To Begin Initial Enrollment In Q3 2024
corvus pharmaceuticals宣佈，其新藥Soquelitinib在治療複發性或難治性PTCL方面已獲得FDA快速通道認證；第3期臨床試驗將於2024年Q3開始初始招募。
Corvus Pharmaceuticals Announces FDA Fast Track Designation For Soquelitinib In Treatment Of Relapsed Or Refractory PTCL; Phase 3 Clinical Trial To Begin Initial Enrollment In Q3 2024
corvus pharmaceuticals宣佈，其新藥Soquelitinib在治療複發性或難治性PTCL方面已獲得FDA快速通道認證；第3期臨床試驗將於2024年Q3開始初始招募。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間